Last updated: 12 September 2022 at 5:09pm EST

Eric Richman Net Worth




The estimated Net Worth of Eric I Richman is at least $864 mil dollars as of 1 March 2022. Mr. Richman owns over 3,880 units of NeuBase Therapeutics stock worth over $16,995 and over the last 10 years he sold NBSE stock worth over $0. In addition, he makes $847,371 as Independent Director at NeuBase Therapeutics.

Mr. Richman NBSE stock SEC Form 4 insiders trading

Eric has made over 7 trades of the NeuBase Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 3,880 units of NBSE stock worth $6,363 on 1 March 2022.

The largest trade he's ever made was buying 25,000 units of NeuBase Therapeutics stock on 9 November 2017 worth over $53,750. On average, Eric trades about 2,812 units every 127 days since 2014. As of 1 March 2022 he still owns at least 44,960 units of NeuBase Therapeutics stock.

You can see the complete history of Mr. Richman stock trades at the bottom of the page.





Eric Richman biography

Eric I. Richman serves as Independent Director of the Company. Mr. Richman was previously a Venture Partner at Brace Pharma Capital, a life science venture capital firm, from January 2016 to September 2018 and is involved with several private and public biotechnology companies. He also served as Chief Executive Officer of Tyrogenex Inc., a biopharmaceutical company, from 2016 to 2018. Mr. Richman served as the President and Chief Executive Officer of PharmAthene, Inc. (“PharmAthene”), subsequently acquired by Altimmune, Inc., between October 2010 and March 2015. He also served on PharmAthene’s board of directors, when the company was listed on the NYSE, from 2010 to 2017. Prior to joining PharmAthene, Mr. Richman held various commercial and strategic positions of increasing responsibility over a 12-year period at MedImmune, Inc. from its inception and was Director, International Commercialization at that company. Mr. Richman served as a director of Lev Pharmaceuticals, Inc. (acquired by Viropharma) and as Chairman of its Commercialization Committee and served as a director of American Bank Incorporated (acquired by Congressional Bancshares). Mr. Richman currently serves as a director of Adma Biologics, Inc. (Nasdaq: ADMA) (as well as a member of such board’s audit, compensation and governance and nominating committees), Zyversa Pharmaceuticals, Inc., NovelStem International Corp. (OTCMKTS: NSTM), co-founder and director of InFuse Holdings and LabConnect, Inc. where he serves as the Chairman of the Board. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a M.B.A. from the American Graduate School of International Management.

What is the salary of Eric Richman?

As the Independent Director of NeuBase Therapeutics, the total compensation of Eric Richman at NeuBase Therapeutics is $847,371. There are 2 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.



What's Eric Richman's mailing address?

Eric's mailing address filed with the SEC is C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR, , PITTSBURGH, PA, 15219.

Insiders trading at NeuBase Therapeutics

Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan, eSamuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.



What does NeuBase Therapeutics do?

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.



What does NeuBase Therapeutics's logo look like?

NeuBase Therapeutics, Inc. logo

Complete history of Mr. Richman stock trades at Adma Biologics Inc e NeuBase Therapeutics

Data
#
Companhia
Acionista maioritário
Trans.
Transação
Ações Preço por ação Preço total Ações após Fonte
1 Mar 2022 Eric I Richman
Diretor
Comprar 3,880 $1.64 $6,363
1 Mar 2022
44,960
26 Apr 2021 Eric I Richman
Diretor
Comprar 5,000 $5.00 $25,000
26 Apr 2021
41,080
30 Apr 2020 Eric I Richman
Diretor
Comprar 10,833 $6.00 $64,998
30 Apr 2020
36,080
8 Jun 2018 Eric I Richman
Diretor
Comprar 5,230 $4.78 $24,999
8 Jun 2018
36,530
9 Nov 2017 Eric I Richman
Diretor
Comprar 25,000 $2.15 $53,750
9 Nov 2017
31,300
13 Jul 2017 Eric I Richman
Diretor
Exercício de opção 2,800 $2.68 $7,504
13 Jul 2017
6,300
13 Mar 2015 Eric I Richman
Diretor
Comprar 3,500 $7.88 $27,580
13 Mar 2015
3,500


NeuBase Therapeutics executives and stock owners

NeuBase Therapeutics executives and other stock owners filed with the SEC include: